AmgenSTU:AMG +0.24%87 Net Margin % is 21.11% as of Mar. 2026, which is 13% below its 10-year median of 24.36. GuruFocus rates STU:AMG with a GF Score™ of 87/100 and a GF Value™ of €310.99 (Fairly Valued). The stock has 6 warning signs investors should review. Among 956 Drug Manufacturers companies, Amgen ranks better than 88.18% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Amgen's Net Income for the
three
months ended in Mar. 2026 was €1,573 Mil. Amgen's Revenue for the
three
months ended in Mar. 2026 was €7,455 Mil. Therefore, Amgen's net margin for the quarter that ended in Mar. 2026 was 21.11%.
The historical rank and industry rank for Amgen's Net Margin % or its related term are showing as below:
STU:AMG'
s Net Margin % Range Over the Past 10 Years
Min: 8.66 Med: 24.36 Max: 35.35
Current: 20.96
STU:AMG's Net Margin % is ranked better than 88.18% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs STU:AMG: 20.96
Amgen (STU:AMG) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Amgen Net Margin % Related Terms
Amgen Net Margin % Historical Data
* Premium members only.
The historical data trend for Amgen's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AMG vs GILD, PFE, BMY: Net Margin % Comparison
For the Drug Manufacturers - General subindustry, Amgen's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's Net Margin % distribution charts can be found below:
* The bar in red indicates where Amgen's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen (STU:AMG) has a Net Margin % of 21.11% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Amgen and its competitors. This is 13% below median its historical median of 24.36. Over the past decade, Amgen's Net Margin % has ranged from 8.66 to 35.35. According to the industry distribution chart, Amgen ranks #113 out of 956 companies in the Drug Manufacturers industry, placing it in the top 11.8%.
Is Amgen's Net Margin % too high?
Amgen's current Net Margin % of 21.11% is 13% below median its 10-year median of 24.36. Over the past 10 years, this metric has ranged from a low of 8.66 to a high of 35.35. The Drug Manufacturers industry median Net Margin % is 5.56. Amgen's value of 21.11% is 279.7% above this industry median. Based on the distribution chart, Amgen ranks #113 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Amgen has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Net Margin % compare to GILD and PFE?
According to the Drug Manufacturers industry distribution chart, Amgen ranks #113 out of 956 companies for Net Margin %. This places Amgen in the top 12% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. Amgen's value of 21.11% is 279.7% above this benchmark. Historically, Amgen's own Net Margin % has ranged from 8.66 to 35.35 over the past decade. While the company's 10-year median is 24.36 vs. the industry median of 5.56, Amgen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amgen's current Net Margin % of 21.11% is 279.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Amgen and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amgen's current Net Margin % is 21.11%, which is 13% below median its own 10-year median of 24.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (STU:AMG) is currently considered Fairly Valued. The stock's GF Value™ is €310.99, compared to a current price of €310.35 — trading 0.2% below its estimated fair value. The current Net Margin % is 21.11%, which is 13% below median its 10-year median of 24.36 and 279.7% above the Drug Manufacturers industry median of 5.56. Amgen's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Amgen (STU:AMG), the current Net Margin % is 21.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amgen (STU:AMG) Overvalued in 2026?
Based on GuruFocus' analysis, Amgen stock appears to be undervalued.
The current stock price of €310.35 is trading 0.2% below its estimated GF Value™ of €310.99.
GuruFocus considers Amgen to be Fairly Valued.
Key valuation signals for STU:AMG:
Net Margin %: 21.11% (13% below median its 10-year median of 24.36)
GF Value™: €310.99 vs. price of €310.35 (0.2% below fair value)
Industry Position: 279.7% above the Drug Manufacturers median (#113 of 956)
No single metric tells the full story. See the STU:AMG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
87GF Score
Get the complete analysis for STU:AMG
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AMG has been successfully added to your 
